ashermans syndrome epidemiology forecast

• The rise in Asherman’s syndrome cases is driven by increased rates of uterine interventions such as curettage, especially following miscarriages and abortions, which can cause intrauterine adhesions. Enhanced physician awareness and advances in diagnostic techniques are also revealing more cases that previously went undetected.
• Asherman’s syndrome develops when trauma to the uterine lining often from surgical procedures, damages the basal endometrium, triggering inflammation and abnormal healing. This leads to the formation of fibrous scar tissue (intrauterine adhesions) that can partially or completely block the uterine cavity, disrupting normal menstrual function and fertility. 
• Diagnosing Asherman’s syndrome remains challenging due to its subtle, nonspecific symptoms and the limited sensitivity of routine imaging techniques like ultrasound. Although hysteroscopy is the most reliable diagnostic tool, its limited accessibility often delays detection. The absence of standardized classification systems further complicates diagnosis and impedes research, contributing to under recognition of the condition’s true burden.
• Asherman’s syndrome is a recognized complication following uterine interventions, with a notably higher incidence in women undergoing dilation and curettage after late spontaneous abortion compared to those treated during early pregnancy termination. This pattern underscores the impact of procedural timing and uterine trauma on the development of intrauterine adhesions.

DelveInsight’s “Asherman’s Syndrome – Epidemiology Forecast – 2034” report delivers an in-depth understanding of Asherman’s Syndrome, historical and forecasted epidemiology trends in the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan. 

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2020–2034

Asherman’s Syndrome Understanding

Asherman’s Syndrome Overview

Asherman syndrome is a rare gynecological condition involving the formation of scar tissue within the uterus, also referred to as intrauterine adhesions (IUA), uterine synechiae, or intrauterine synechiae. Its true prevalence is uncertain, partly due to underreporting, especially in individuals not trying to conceive who may remain asymptomatic. Asherman syndrome typically occurs in the context of post-abortion, postpartum, or post-surgical uterine trauma. Estimates suggest it affects about 13% of those undergoing a first-trimester abortion, approximately 30% of individuals having a dilation and curettage (D&C) after a late pregnancy loss, and around 23.4% of those requiring repeat procedures 2–4 weeks after vaginal delivery or a missed abortion.

Asherman’s Syndrome Diagnosis

To diagnose Asherman’s syndrome, imaging tests are initially used to evaluate the uterus, but they often lack specificity. Hysteroscopy remains the most accurate method, allowing direct visualization of intrauterine adhesions; however, its limited availability can lead to missed or delayed diagnoses. As an alternative, hysterosalpingography (HSG) uses contrast dye and X-rays to reveal scarring. While ultrasound and MRI cannot directly detect adhesions, ultrasound may indicate indirect signs suggestive of the condition.

Further details related to diagnosis are provided in the report…

Want to know the upcoming therapies, market drivers, market forecast and growth opportunities? Check Here Asherman's Syndrome Market Report

Asherman’s Syndrome Epidemiology

The Asherman’s syndrome epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total incident cases of Asherman’s syndrome, and type–specific incident cases of Asherman’s syndrome in the 7MM covering, the United States, EU4 countries (Germany, France, Italy, and Spain), United Kingdom, and Japan from 2020 to 2034.

• According to the secondary analysis, in the US, Asherman’s syndrome may occur in up to 13% of women undergoing a termination of pregnancy during the first trimester, and 30% in women undergoing a dilation and curettage (D and C) after a late spontaneous abortion.
• In the US, Asherman's syndrome incidence may be as high as 23.4% in patients undergoing procedures two to four weeks after the initial procedure for a vaginal delivery or missed abortion. 
• As per the secondary research, there is no exact number of women in the UK who experience Asherman’s syndrome, as it is often misdiagnosed or not diagnosed at all. However, it is estimated that around 1 in 1,000 women in the UK may have the condition.

KOL Views

DelveInsight’s analysts collaborated with over 30+ key opinion leaders (KOLs), conducting in-depth interviews with more than 15+ experts across the 7MM. To keep pace with dynamic market trends, the team gathered first-hand insights from KOLs and subject matter experts (SMEs) through primary research, addressing data limitations and reinforcing findings from secondary research. These professionals offered valuable input on the Asherman’s syndrome landscape, highlighting patient behavior trends, and challenges in access to care. Contributors included experts from renowned institutions such as the University of Texas Health Science Center, US; University of Catania, Italy; Society of Obstetrics and Gynecology, and Japan; Obstetrics and Gynecology Unit, Italy, among others.

“Diagnosing Asherman syndrome can be particularly challenging due to its often subtle or nonspecific symptoms, such as menstrual irregularities or infertility. Accurate diagnosis typically requires a coordinated, interprofessional approach involving an obstetrician, gynecologist, and radiologist. Imaging techniques like hysterosalpingography, sonohysterography, and MRI may be utilized to evaluate the extent and location of intrauterine adhesions.”

“Asherman’s syndrome remains an underdiagnosed condition with several unmet needs. There is no standardized screening protocol following high-risk uterine procedures, leading to delays in diagnosis until complications such as infertility arise. Limited awareness among healthcare providers further contributes to under recognition. Additionally, there is a lack of clear clinical guidelines for monitoring placental attachment and adhesions in subsequent pregnancies, posing risks for recurrence and pregnancy complications.”

“Asherman syndrome is a rare but clinically significant acquired condition characterized by the formation of intrauterine adhesions, leading to partial or complete obliteration of the uterine cavity. These adhesions, often fibrous in nature, typically involve at least two-thirds of the endometrial surface and may obstruct the internal cervical os. The condition frequently arises following uterine trauma, most commonly after procedures such as dilation and curettage (D&C), particularly when performed postpartum or after miscarriage.”

Scope of the Report

• The report covers a segment of executive summary, descriptive overview of Asherman’s syndrome, explaining its causes, signs and symptoms, and currently available diagnostic algorithms and guidelines.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and diagnosis guidelines.
• The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
• A detailed review of current challenges in establishing the diagnosis.

Asherman’s Syndrome Report Insights

• Patient Population
• Country-wise Epidemiology Distribution
• Asherman’s Syndrome Pipeline Analysis
• Total Incident  Cases of Asherman’s syndrome
• Type-specific Incident Cases of Asherman’s syndrome

Asherman’s Syndrome Report Key Strengths

• 10 years Forecast
• The 7MM Coverage 
• Key Cross Competition 
• Attribute Analysis

Key Questions

Epidemiology Insights

• What are the disease risk, burden, and unmet needs of Asherman’s syndrome?
• What is the historical Asherman’s syndrome patient population in the United States, EU4 (Germany, France, Italy, Spain) and the UK, and Japan?
• What would be the forecasted patient population of Asherman’s syndrome at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Asherman’s syndrome?
• Out of the above-mentioned countries, which country would have the highest incident population of Asherman’s syndrome during the forecast period (2025–2034)?
• At what Compound annual growth rate (CAGR) the population is expected to grow across the 7MM during the forecast period (2025–2034)?

Reasons to Buy

• Insights on patient burden/disease Incident, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To analyze epidemiological trends of Asherman’s syndrome across different regions and assess how these patterns may evolve in the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
• To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis options.

Frequently Asked Questions

1. What is the forecast period covered in the report?

The Asherman's syndrome epidemiology report for the 7MM covers the forecast period from 2025 to 2034, providing a projection of epidemiology dynamics and trends during this timeframe.

2. What are the challenges in diagnosis of Asherman's syndrome?

Diagnosing Asherman’s syndrome is complicated by its often subtle or non-specific symptoms, such as irregular menstruation or infertility, which can be mistaken for other conditions. Additionally, the gold-standard diagnostic tool—hysteroscopy—is not universally available, and conventional imaging like ultrasound may miss intrauterine adhesions, leading to underdiagnosis or delayed recognition. 

3. How is epidemiological data collected and analyzed for forecasting purposes?

To anticipate future disease patterns, researchers aggregate data from clinical registries, population-based studies, and hospital records. This information is then synthesized using statistical modeling to estimate current prevalence, identify emerging trends, and predict how the disease burden may evolve over time.